New CEO at Polyplus-transfection
This article was originally published in Scrip
Polyplus-transfection (France), a privately held company developing solutions for molecular and cellular biology, today has appointed Mark Bloomfield CEO. He succeeds Frédéric Perraud, who continues as chief operating officer and deputy CEO. Mr Bloomfield has more than 15 years' senior sales, commercial leadership and business management experience with companies working in biotechnology tools and analytical instruments.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.